Evidence map›Paper›PMID 34671472›Full record

ArticleMolecular and clinical oncology2021

Capecitabine-induced hand-foot syndrome does not emerge in the complex regional pain syndrome-affected limb: A case report.

Reo Inoue, Hiroaki Abe, Mitsuru Konishi, Rikuhei Tsuchida, Tatsuma Edamura, Masahiko Sumitani

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Molecular and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Reo InoueAnesthesiology and Pain Relief Centre, The University of Tokyo Hospital, Tokyo 113-0033, Japan.
Hiroaki AbeDepartment of Pain and Palliative Medicine, The University of Tokyo Hospital, Tokyo 113-0033, Japan.
Mitsuru KonishiDepartment of Pain and Palliative Medicine, The University of Tokyo Hospital, Tokyo 113-0033, Japan.
Rikuhei TsuchidaAnesthesiology and Pain Relief Centre, The University of Tokyo Hospital, Tokyo 113-0033, Japan.
Tatsuma EdamuraAnesthesiology and Pain Relief Centre, The University of Tokyo Hospital, Tokyo 113-0033, Japan.
Masahiko SumitaniDepartment of Pain and Palliative Medicine, The University of Tokyo Hospital, Tokyo 113-0033, Japan.
University of Tokyo Hospital · JPThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hand-foot syndrome (HFS) is a frequent adverse effect of various anti-tumour drugs, such as capecitabine, that affects their dose-limiting toxicity. The mechanism of HFS remains unknown and there are currently no effective strategies to treat HFS, except for cessation. The current study presented a female case where one hand, affected by brachial plexus infiltration due to the subclavian lymph node metastasis of breast cancer, exhibited not only pain and partial motor paralysis but also anhidrosis, oedema and skin colour changes. The patient met the diagnostic criteria for complex regional pain syndrome (CRPS). After treatment with capecitabine, their anhidrosis hand completely prevented HFS. The other hand and both feet demonstrated typical symptoms of HFS, which improved consequent to capecitabine cessation. The CRPS-affected hand remained normal. Considering the limited presentation of HFS concomitant with anhidrosis, the exocrine release of condensed capecitabine through sweat glands might be a promising mechanism of HFS induction.

Indexed as

anhidrosisbreast cancercapecitabinecomplex regional pain syndromehand-foot syndrome

Identifiers

PMID34671472
PMCPMC8521386
OpenAlexW3205523901

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.